Pancreatic and Hepatic Oncology Research

This study profiles the pancreatic microbiome in patients with benign, precancerous, and cancerous conditions, finding a low-biomass, low-diversity microbiome that does not differ across disease states.

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.

This study shows that mesenchymal pancreatic ductal adenocarcinoma cells depend on the PP2A subunit PR130, and its inhibition by phendione leads to apoptosis and protein aggregate formation.

This study identifies LMO3 as a suppressor of the aggressive basal-like/squamous PDAC subtype, showing it reduces disease aggressiveness through modulation of glycerol 3-phosphate metabolism.

This study compares two orthotopic PDAC mouse models to evaluate their suitability for studying adoptive T cell therapy, finding that the MT-5 model better replicates the stromal features of human PDAC.

This study shows that Acvr1b loss in combination with Kras mutation promotes precancerous lesions from both acinar and ductal cells in the pancreas, but the IPMN-like phenotype differs when mutations occur in all cells.

This study identifies a specific subset of tumor-associated endothelial cells in PDAC and develops a prognostic model, TaEMS, to predict patient outcomes based on immune and cellular pathway profiles.

This study shows EN1 promotes pancreatic cancer metastasis by repressing target genes and enhancing mesenchymal properties.

This study shows that inhibiting stromal Class I HDACs reduces pancreatic cancer progression by targeting desmoplastic and pro-tumorigenic programs in cancer-associated fibroblasts.

This study shows that combining lurbinectedin with irinotecan and 5-FU significantly enhances the killing of pancreatic cancer cells.

This study compares molecular features of young-onset and average-onset pancreatic cancer using multi-omic data, finding distinct mutation patterns and immune profiles with prognostic implications.

The paper develops an AI-derived prognostic signature for pancreatic cancer using multi-center cohorts and machine learning, showing improved predictive performance and clinical relevance.

This study evaluates three PDAC molecular signatures across eight datasets, finding inconsistent subtyping and low classification accuracy, suggesting technical biases and the need for multi-omic approaches.

The paper identifies differentially expressed genes and modules associated with long-term survival in PDAC patients using integrative transcriptome analysis.

This study identifies two distinct pancreatic cancer subtypes through proteogenomic analysis and links them to altered molecular pathways and clinical outcomes.

The paper identifies a transcriptionally distinct subpopulation of healthy acinar cells with features of pancreatic progenitors and PDAC, linked to poor patient survival and age-related changes.

The paper uses a multi-layered approach combining GWAS, spatial autocorrelation, and Hi-C to identify novel genetic variants associated with pancreatic cancer susceptibility.

This study shows HNF1A recruits UTX to activate a differentiation program that suppresses pancreatic cancer by remodeling enhancers and inhibiting oncogenic pathways.

This study identifies blood-based biomarkers and therapeutic agents for PDAC using network analysis of microarray data from peripheral blood samples.

The paper develops a prognostic model for pancreatic ductal adenocarcinoma using meta-analysis of transcriptomic data, identifying gene pairs associated with early mortality after surgery.

The paper compares whole-genome data from primary pancreatic cancer, xenografts, and organoids to assess genetic concordance across different models.